A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Gynecologic Oncology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2011.02.013PMID 21414654PMCID PMC3100412
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The proof and measurement of association between two things.

  2015cited by this paper
• A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials

  2012cited by this paper
• Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

  2011cited by this paper
• A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.

  2010cited by this paper
• A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.

  2010cited by this paper
• Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.

  2008cited by this paper
• A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

  2008cited by this paper
• Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma

  2008cited by this paper
• A Method for Utilizing Bivariate Efficacy Outcome Measures to Screen Agents for Activity in 2-Stage Phase II Clinical Trials

  2008cited by this paper
• Protein kinase C isozymes as therapeutic targets for treatment of human cancers.

  2008cited by this paper
• Deregulation of the Akt pathway in human cancer.

  2008cited by this paper
• Enzastaurin

  2008cited by this paper
• Enzastaurin

  2007cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

  2006cited by this paper
• Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.

  2006cited by this paper
• Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor

  2006cited by this paper
• Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.

  2006influential reference
• Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

  2006influential reference
• [Research on the mechanisms of PTEN gene inactivation in ovarian cancer].

  2005cited by this paper
• Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers

  2005cited by this paper
• Treatment goals in ovarian cancer

  2005cited by this paper
• The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

  2005cited by this paper
• A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.

  2004cited by this paper
• The biology and clinical relevance of the PTEN tumor suppressor pathway.

  2004cited by this paper
• PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways

  2004cited by this paper
• A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma

  2004cited by this paper
• LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

  2004cited by this paper
• A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

  2003cited by this paper
• Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.

  2003cited by this paper
• A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study

  2003cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Resistant Ovarian Cancer: A Gynecologic Oncology Group Study

  2002cited by this paper
• Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

  2001cited by this paper
• A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

  2001cited by this paper
• Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.

  2001cited by this paper
• Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.

  2000cited by this paper
• Allelic imbalance and mutations of the PTEN gene in ovarian cancer

  2000cited by this paper
• Secretion of vascular endothelial growth factor in ovarian cancer.

  1999influential reference
• Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.

  1999cited by this paper
• Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.

  1998cited by this paper
• Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group.

  1998cited by this paper
• Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group

  1998cited by this paper
• Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

  1995influential reference
• AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

  1992influential reference
• Cancer statistics

  1989cited by this paper
• The proof and measurement of association between two things. By C. Spearman, 1904.

  1987cited by this paper
• Nonparametric Statistical Methods

  1974influential reference
• The treatment of ties in ranking problems.

  1945cited by this paper
• Statistical Methods for Research Workers

  1937cited by this paper
• Statistical Methods for Research Workers

  1930cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• PKC in cancer: A dual role in cancer promotion and suppression

  2025cites this paper
• Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response

  2023cites this paper
• Amplified therapeutic targets in high-grade serous ovarian carcinoma – a review of the literature with quantitative appraisal

  2023cites this paper
• An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases

  2023cites this paper
• Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

  2021cites this paper
• Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer

  2021cites this paper
• Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer

  2021cites this paper
• ANTITUMOR DRUGS BASED ON INDOLOCARBAZOL DERIVATIVES

  2021cites this paper
• Evaluating the current status of protein kinase C (PKC)-protein kinase D (PKD) Signalling Axis as a novel therapeutic target in ovarian Cancer.

  2020cites this paper
• PKCβII specifically regulates KCNQ1/KCNE1 channel membrane localization.

  2019cites this paper
• Kinase Inhibitors and Ovarian Cancer

  2019cites this paper
• Molecular Carcinogenesis

  2019cites this paper
• Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions.

  2018cites this paper
• Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

  2018cites this paper
• Investigation Regarding the Properties of Protein Kinase Cθ Selective Inhibitor as a Novel T cell Immunosuppressant

  2017cites this paper
• Clinical trials in gynecologic oncology: Past, present, and future.

  2017cites this paper
• Identification of licofelone through three-dimensional cell culture drug screening as a repurposed agent able to reverse drug resistant and cancer stem cell-like subpopulations in ovarian cancer

  2017cites this paper
• A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma

  2016cites this paper
• Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1)

  2016cites this paper
• An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

  2016cites this paper
• Effect of novel PKCθ selective inhibitor AS2521780 on acute rejection in rat and non-human primate models of transplantation.

  2015cites this paper
• Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma.

  2015cites this paper
• Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma.

  2015cites this paper
• A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

  2014cites this paper
• Novel therapies, including enzastaurin, in the treatment of ovarian cancer

  2014cites this paper
• Targeting protein kinase C in sarcoma.

  2014cites this paper
• Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data

  2014cites this paper
• Novel Targeted Therapies in Ovarian Cancer

  2014cites this paper
• Title Integrative Pathway Analysis Using Graph-Based Learning withApplications to TCGA Colon and Ovarian Data

  2014cites this paper
• Perspective of strategic plasma therapy in patients with epithelial ovarian cancer: A short review of plasma in cancer treatment

  2014cites this paper
• Pathway Modulations and Epigenetic Alterations in Ovarian Tumorbiogenesis

  2014cites this paper
• Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.

  2013cites this paper
• Perspective of strategic plasma therapy for prognostic improvement of patients with ovarian cancer

  2013cites this paper
• Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer

  2013cites this paper
• Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment

  2013influential citation
• Kinase inhibitors of marine origin.

  2013cites this paper
• Effect of Indirect Nonequilibrium Atmospheric Pressure Plasma on Anti-Proliferative Activity against Chronic Chemo-Resistant Ovarian Cancer Cells In Vitro and In Vivo

  2013cites this paper
• A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

  2013cites this paper
• Structure-activity studies on the side chain of a simplified analog of aplysiatoxin (aplog-1) with anti-proliferative activity.

  2013cites this paper
• A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.

  2012cites this paper
• Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.

  2012cites this paper
• Potential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review

  2012cites this paper
• Clinical trials and future potential of targeted therapy for ovarian cancer

  2012cites this paper
• A double‐blind, randomized, placebo‐controlled, phase 2 study of maintenance enzastaurin with 5‐fluorouracil/leucovorin plus bevacizumab after first‐line therapy for metastatic colorectal cancer

  2012cites this paper
• Clinical utility of targeted treatments in the management of epithelial ovarian cancer

  2012cites this paper
• Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics

  2012cites this paper
• High nuclear protein kinase CβII expression is a marker of disease recurrence in oral squamous cell carcinoma.

  2012cites this paper
• Protein kinase C, an elusive therapeutic target?

  2012cites this paper
• A Rational Approach to the Management of Recurrent or Persistent Ovarian Carcinoma

  2012cites this paper
• Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

  2011cites this paper
• Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

  2011cites this paper
• Supplementary Issue: Array Platform Modeling and Analysis (a)

  year unknowncites this paper